Anna Isotta Castrini
- Cardiologist, PhD fellow; MD
Anna Isotta Castrini, MD, is cardiologist and PhD fellow at last year at Department of Cardiology, OUS, Rikshospitalet. She is supervised by Prof. Kristina Haugaa, Dr. Øyvind Lie, MD, PhD and Dr. Mette Estensen MD, PhD. Inherited cardiomyopathies are the main topic of her PhD project, with focus on effect of pregnancy on disease’s penetrance and progression. With the research group, she published two important papers on the effect of pregnancy in arrhythmogenic cardiomyopathy and Lamin A/C cardiomyopathy, recently included in the European guidelines for management of cardiomyopathies. During her research fellowship, Dr. Castrini was awarded by “Best poster Price” during the Annual Symposium for Heart Research.
Dr. Castrini has a special interest for echocardiography and she is certified by the European Association
for Cardiovascular Imaging for trans-thoracic echocardiography in adults.
Sudden cardiac death in the young-Can illicit drug use explain the unexplained?
Heart Rhythm (in press)
The added value of abnormal regional myocardial function for risk prediction in arrhythmogenic right ventricular cardiomyopathy
Eur Heart J Cardiovasc Imaging (in press)
Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum
J Am Coll Cardiol, 82 (9), 785-797
Pregnancy and Progression of Cardiomyopathy in Women With LMNA Genotype-Positive
J Am Heart Assoc, 11 (8), e024960
The response to cardiac resynchronization therapy in LMNA cardiomyopathy
Eur J Heart Fail, 24 (4), 685-693
Progression of cardiac disease in patients with lamin A/C mutations
Eur Heart J Cardiovasc Imaging, 23 (4), 543-550
Sex differences in disease progression and arrhythmic risk in patients with arrhythmogenic cardiomyopathy
Europace, 23 (7), 1084-1091
Pregnancies, ventricular arrhythmias, and substrate progression in women with arrhythmogenic right ventricular cardiomyopathy in the Nordic ARVC Registry
Europace, 22 (12), 1873-1879
Absence of ECG Task Force Criteria does not rule out structural changes in genotype positive ARVC patients
Int J Cardiol, 317, 152-158
Reply to: TFC ECG in arrhythmogenic cardiomyopathy: Inadequate mixture of criteria?
Int J Cardiol, 323, 203
Number of pregnancies and subsequent phenotype in a cross-sectional cohort of women with arrhythmogenic cardiomyopathy
Eur Heart J Cardiovasc Imaging, 20 (2), 192-198
Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure
J Cardiovasc Med (Hagerstown), 18 (11), 859-865
N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure
J Cardiovasc Med (Hagerstown), 17 (11), 828-39
Amino acids and derivatives, a new treatment of chronic heart failure?
Heart Fail Rev, 20 (1), 39-51
Serelaxin a novel treatment for acute heart failure
Expert Rev Clin Pharmacol, 8 (5), 549-57
Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure
Panminerva Med, 58 (1), 8-15
Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure
Nutrition, 31 (1), 72-8
[Efficacy of ACE-inhibitors in patients with recent myocardial infarction. Studies with zofenopril]
G Ital Cardiol (Rome), 13 (10 Suppl 2), 55S-58S